

ASIAN INVESTMENT SERIES 2018

13 March 2018 KPMG Hong Kong 15-16 March 2018 KPMG Shanghai

HONG KONG BIOTECH INVEST & PARTNERING

AUSTRALIA-CHINA BIOTECH INVEST & PARTNERING



GlyTherix

GlyTherix Ltd

Company Description

GlyTherix (currently a subsidiary of Minomic International Ltd) is an Australian Immuno-Oncology Company with unique assets in the treatment of solid tumors with high unmet need. GlyTherix has:

- The ability to address a clear market need for new therapies to target solid tumors.
- A clear development pathway.
- A clear understanding of the requirements for the pipeline development programs.
- The leadership team needed to manage the planned research programs.
- A clear end goal which is to maximize the return on its intellectual property assets.

Pipeline and Developments


Miltuximab® (our patented antibody) targets Glypican-1 (GPC-1), a protein overexpressed in prostate, pancreatic, bladder, esophageal and other solid tumors.

We have commenced a first in human trial using Miltuximab® to evaluate the safety and tumor targeting of Miltuximab® in patients with advanced prostate, bladder and pancreatic cancer. We have now dosed a total of 9 patients with no drug-related adverse reactions whatsoever.

Miltuximab® is a first in class product. No-one else presently has an anti-glypican-1 therapy, in clinical development, for these cancers. For any antibody-based therapy one should not only be the first but also the best in class.

To achieve this GlyTherix is developing pipeline with:

- The best version of the antibody; which is most effective and safe as well as acceptable to our future licensee partners.
- The best cell killing payload; which is most effective and well tolerated by the patient.



What we are looking for:

GlyTherix is raising capital to fund the commercialization of Miltuximab®, that targets cancers that have a major underserved need, in a high value market, with the protection of a growing intellectual property position (5 families of applications) and a reduced commercial risk profile.

Contact:

Name: Brad Walsh
 Position: Executive Director
 Company: GlyTherix Ltd
 Address: Ground Floor, 75 Talavera Road, Macquarie Park NSW 2113
 Website: glytherix.com
 Phone: +61 413 231 296
 Email: brad.walsh@minomic.com

For more information, please visit www.australiabiotechinvest.com.au

Follow us for the latest event update #AusBioInv